Assignee
CUREVAC GMBH
DE·9 granted patents·17 pending applications·629 citations·filing 2005–2015
Top patents by PatentIndex Score
26 records- 0198US9683233B2Artificial nucleic acid molecules for improved protein or peptide expressionCUREVAC GMBH·Filed 2013·Granted Jun 20, 2017·61 cites·22 claims
- 0298US9669089B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC GMBH·Filed 2013·Granted Jun 6, 2017·107 cites·21 claims
- 0398US9616084B2Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acidsCUREVAC GMBH·Filed 2014·Granted Apr 11, 2017·68 cites·20 claims
- 0498US9447431B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC GMBH·Filed 2013·Granted Sep 20, 2016·70 cites·16 claims
- 0598US9155788B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC GMBH·Filed 2014·Granted Oct 13, 2015·64 cites·20 claims
- 0696US9314535B2Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acidsCUREVAC GMBH·Filed 2014·Granted Apr 19, 2016·32 cites·15 claims
- 0795US8383340B2Method for purifying RNA on a preparative scale by means of HPLCCUREVAC GMBH·Filed 2007·Granted Feb 26, 2013·164 cites·26 claims
- 0894US9890391B2RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loopCUREVAC GMBH·Filed 2013·Granted Feb 13, 2018·30 cites·16 claims
- 0994US9352028B2Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)CUREVAC GMBH·Filed 2013·Granted May 31, 2016·33 cites·67 claims
- 1071US2010203076A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC GMBH·Filed 2008·Application pending·0 cites
- 1169US2011053829A1Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acidsCUREVAC GMBH·Filed 2009·Application pending·0 cites
- 1265US2013195867A1Rna-coded antibodyCUREVAC GMBH·Filed 2012·Application pending·0 cites
- 1364US2009324584A1Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/AdjuvantCUREVAC GMBH·Filed 2007·Application pending·0 cites
- 1463US2013273001A1Immunostimulation by chemically modified rnaCUREVAC GMBH·Filed 2013·Application pending·0 cites
- 1561US2011269950A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC GMBH·Filed 2011·Application pending·0 cites
- 1658US2011077287A1Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regionsCUREVAC GMBH·Filed 2010·Application pending·0 cites
- 1758US2015118183A1Negatively charged nucleic acid comprising complexes for immunostimulationCUREVAC GMBH·Filed 2013·Application pending·0 cites
- 1858US2015118264A1Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigenCUREVAC GMBH·Filed 2013·Application pending·0 cites
- 1958US2007280929A1Adjuvant in the form of a lipid-modified nucleic acidCUREVAC GMBH·Filed 2007·Application pending·0 cites
- 2058US2010239608A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC GMBH·Filed 2010·Application pending·0 cites
- 2157US2010303851A1Immunostimulation by chemically modified rnaCUREVAC GMBH·Filed 2010·Application pending·0 cites
- 2256US2008267873A1Injection Solution for RnaCUREVAC GMBH·Filed 2006·Application pending·0 cites
- 2356US2015258214A1Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulationCUREVAC GMBH·Filed 2015·Application pending·0 cites
- 2453US2015306249A1Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatingsCUREVAC GMBH·Filed 2012·Application pending·0 cites
- 2552US2008171711A1Mrna Mixture For Vaccinating Against Tumoral DiseasesCUREVAC GMBH·Filed 2005·Application pending·0 cites
- 2643US2010047261A1Base-modified rna for increasing the expression of a proteinCUREVAC GMBH·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CUREVAC GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →